Starting in late March 2018, all drug screen tests at our Burnaby lab will move from the current Roche Integra 800 instrument to a new Siemens platform. Lab reports will indicate tests where the methodology has changed. Note that the new tests may cross-react differently than the existing method with related compounds: please refer to our website for complete cross reactivity tables. All cut-off levels will be unchanged with the exception of buprenorphine, which is changing from 5 ng/mL to 10 ng/mL, as the new method cross-reacts with both parent drug and metabolites.
Jan Palaty, PhD, FCACB, Clinical Biochemist